Metraipolis › archive › dc_2f906056ff42

Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study — Europe PMC PMID:42201004

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42201004
DOI
10.3390/medsci14020212
License (as archived)
solo-consultazione
Archived
2026-11-03T06:55:28.275Z
SHA-256 of the archived text
6cad9deb49a9916c7647361725a308ef35f6027ea32f11a7ed3647535b309fac
Stable URL of this page
https://metraipolis.com/documento/dc_2f906056ff42

How to cite

Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study — Europe PMC PMID:42201004 — Europe PMC (en), https://europepmc.org/article/MED/42201004 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2f906056ff42 (Metraipolis archive dc_2f906056ff42, sha256 6cad9deb49a9916c7647361725a308ef35f6027ea32f11a7ed3647535b309fac)
BibTeX
@misc{dc2f906056ff42,
  title = {Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study — Europe PMC PMID:42201004},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42201004},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2f906056ff42; sha256 6cad9deb49a9916c7647361725a308ef35f6027ea32f11a7ed3647535b309fac},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42201004. Agents can read the archived copy with the MCP tool read_document.